Edition:
United States

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.62USD
14 Dec 2018
Change (% chg)

$-0.01 (-0.61%)
Prev Close
$1.63
Open
$1.61
Day's High
$1.67
Day's Low
$1.58
Volume
15,991
Avg. Vol
63,705
52-wk High
$2.43
52-wk Low
$0.83

Latest Key Developments (Source: Significant Developments)

Vistagen Therapeutics Receives Notices Of Allowance In Australia And Japan For AV-101 Patents Covering Treatment Of Depression
Monday, 12 Nov 2018 08:30am EST 

Nov 12 (Reuters) - VistaGen Therapeutics Inc ::VISTAGEN THERAPEUTICS RECEIVES NOTICES OF ALLOWANCE IN AUSTRALIA AND JAPAN FOR AV-101 PATENTS COVERING TREATMENT OF DEPRESSION.VISTAGEN THERAPEUTICS - RECEIVED NOTICES OF ALLOWANCE FROM IP AUSTRALIA & JAPAN PATENT OFFICE RELATED TO METHODS OF TREATING DEPRESSION WITH AV-101.  Full Article

Vistagen Therapeutics Qtrly Loss Per Share $0.30
Monday, 29 Oct 2018 04:30pm EDT 

Oct 29 (Reuters) - VistaGen Therapeutics Inc ::VISTAGEN THERAPEUTICS REPORTS FISCAL 2019 SECOND QUARTER FINANCIAL RESULTS.VISTAGEN THERAPEUTICS INC - "ELEVATE IS WELL UNDERWAY, AND WE REMAIN CONFIDENT IN OUR TARGET TO DELIVER TOPLINE RESULTS IN MID-2019".VISTAGEN THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.30.VISTAGEN THERAPEUTICS INC - AT SEPTEMBER 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $7.8 MILLION.  Full Article

Vistagen Therapeutics Acquires Worldwide Rights To Develop And Commercialize PH10
Thursday, 25 Oct 2018 09:00am EDT 

Oct 25 (Reuters) - VistaGen Therapeutics Inc ::VISTAGEN THERAPEUTICS ACQUIRES WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE PH10, A FIRST-IN-CLASS INTRANASALLY ADMINISTERED NEUROACTIVE STEROID WITH RAPID-ONSET ANTIDEPRESSANT EFFECTS FOR MAJOR DEPRESSIVE DISORDER DEMONSTRATED IN PHASE 2A STUDY.VISTAGEN THERAPEUTICS INC - IN THIS STUDY, PH10 WAS VERY WELL TOLERATED WITH MINIMAL SIDE EFFECTS.  Full Article

Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101
Wednesday, 3 Oct 2018 08:30am EDT 

Oct 3 (Reuters) - VistaGen Therapeutics Inc ::VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR DEVELOPMENT OF AV-101 AS A NON-OPIOID TREATMENT FOR NEUROPATHIC PAIN.VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR DEVELOPMENT OF AV-101 AS A NON-OPIOID TREATMENT FOR NEUROPATHIC PAIN.  Full Article

Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder
Wednesday, 3 Jan 2018 08:30am EST 

Jan 3 (Reuters) - Vistagen Therapeutics Inc ::VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER.VISTAGEN THERAPEUTICS INC - ‍ON TRACK TO DOSE FIRST PATIENT IN AV-101 PHASE 2 MDD ADJUNCTIVE TREATMENT STUDY IN Q1 OF 2018​.  Full Article

Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13
Wednesday, 20 Dec 2017 05:04pm EST 

Dec 20 (Reuters) - Intracoastal Capital Llc::REPORTS a 9.99 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>>: AS OF DEC 13 - SEC FILING.  Full Article

Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics
Thursday, 14 Dec 2017 10:19am EST 

Dec 14 (Reuters) - Vistagen Therapeutics Inc ::SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>> AS OF DEC 11 - SEC FILING.  Full Article

Vistagen Therapeutics posts Q2 loss of $0.53 per share
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Vistagen Therapeutics Inc :Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update.Qtrly ‍basic and diluted net loss attributable to common stockholders per common share​ of $0.53.  Full Article

VistaGen Therapeutics files for offering of up to $23 mln of common stock
Wednesday, 18 Oct 2017 05:49pm EDT 

Oct 19 (Reuters) - VistaGen Therapeutics Inc :VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​.  Full Article

VistaGen Therapeutics reports Q3 loss per share $0.34
Monday, 13 Feb 2017 04:15pm EST 

VistaGen Therapeutics Inc : VistaGen Therapeutics reports fiscal third quarter 2017 financial results and provides corporate update .Q3 loss per share $0.34.  Full Article